10 July 2013
: Case report
Posterior reversible encephalopathy syndrome in a renal transplanted patient
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Rare disease
Alparslan MerdinABCDEF, Bora UsluABCDEF, Hüseyin KoçakABCDEF, Ayhan DinçkanABCDEF, Gültekin SüleymanlarABCDEFDOI: 10.12659/AJCR.889260
Am J Case Rep 2013; 14:241-244
Abstract
Background: Posterior reversible encephalopathy syndrome (PRES) is characterized by reversible neurological findings with clinical hallmarks such as headache, confusion, seizures, cortical visual disturbances, and other focal neurological signs.
Case Report: A 28-year-old male patient was hospitalized secondary to diarrhea and abdominal pain. He had renal transplantation due to renal amyloidosis secondary to familial Mediterranean fever (FMF). In his clinical follow-up, he had seizures, hemiparesis, blurred vision, and vomited an Ascaris lumbricoides. MRI results led to diagnosis of PRES. Mycophenolate mofetil was changed to everolimus, his systolic blood was pressure kept below 140 mm hg, and his intestinal parasitosis was treated. During follow-up, he had no pain and no diarrhea. His neurological symptoms turned to normal within 48 hours and neuroradiological findings returned to normal within 2 weeks.
Conclusions: PRES is a rare disorder of unknown incidence in renal transplantation patients. Early diagnosis is very important to prevent irreversible neurological sequelae. PRES is totally reversible with cessation of the offending agent, rapid control of hypertension, and treatment of the underlying disease. For early diagnosis and to reduce morbidity and mortality, stool sample examination should be made in patients taking immunosuppressive drugs.
Keywords: familial mediterranean fever related amyloidosis, mycophenolate mofetil usage, Posterior reversible encephalopathy syndrome, renal transplanted patient, intestinal parasitosis
SARS-CoV-2/COVID-19
29 July 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.937105
08 July 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.937212
07 July 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936250
04 July 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.934468
In Press
05 Aug 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.937301
01 Aug 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936361
29 Jul 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.937105
28 Jul 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936690
Most Viewed Current Articles
13 Jul 2022 : Case report
DOI :10.12659/AJCR.936441
Am J Case Rep 2022; 23:e936441
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
06 Dec 2021 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
17 Feb 2022 : Case report
DOI :10.12659/AJCR.934399
Am J Case Rep 2022; 23:e934399